Home > Online Clinic News > Lorcaserin European Application Mooted

Latest News

by Robert MacKay, Tuesday, 31 May 2011 | Categories: Diet Pills

Following the results of meta-analyses of phase III drug trials, Arena presented its findings at the European Congress on Obesity and has demonstrated that Lorcaserin, its weight loss drug candidate, can help the obese shed up to one third of their original body weight. Lorcaserin was trialled as an appetite suppressant where an average of 5.8% of weight was lost by participants over a period of one year and in some cases 40% of weight was lost along with the reduction of harmful levels of cholesterol and blood pressure.

Last year the FDA (Food and Drug Administration) rejected Arena’s application for approval based on its potential to cause the growth of tumours in rats but the company feels confident that this should not have been a concern and is due to present evidence to support its position and next year, the company will seek the approval of the European regulator. If all goes well, it is hoped that the drug will be available from 2013.

The trials involved 7,500 people and it was revealed that 9 out of 10 of the participants noticed a certain amount of weight loss over the period of one year when taking Lorcaserin twice daily.

The drug was not found to be associated with any cardiovascular risk, the main reason other weight loss treatments have recently been taken off the market.





 
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more Close